

# The Dynamic Metastases of Human Ovarian Carcinoma to Grading Lymph Nodes in Mouse Model

**Licheng Du**

Shandong Provincial Hospital affiliated to Shandong university

**Fenghua Kong**

Shandong Provincial hospital affiliated to Shandong university

**Qing Yang**

Shandong Provincial hospital affiliated to Shandong university

**Yaqiong Li**

Shandong Provincial Hospital affiliated to Shandong University

**Peikai Ding**

Shandong Provincial hospital affiliated to Shandong university

**Guoxiang Yu**

Shandong Provincial hospital affiliated to Shandong university

**Yiping Yao**

Shandong Provincial Hospital affiliated to Shandong university

**Yueran Zhao**

Shandong Provincial hospital affiliated to Shandong university

**Xingsong Tian** (✉ [txs0509@163.com](mailto:txs0509@163.com))

Shandong Provincial Hospital affiliated to Shandong university

---

## Research article

**Keywords:** VEGF-D, grading LN metastasis, dynamic observation

**Posted Date:** October 1st, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-67700/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background** Lymphogenous metastasis, one of the most common dissemination routes for ovarian carcinoma, predicts a poor prognosis and relates to most cancer-related death. Now there were no effective therapy and control methods for ovarian carcinoma. Hence, it is necessary to build an animal model of lymph node metastasis in ovarian cancer to seek for the tools to find effective treatments. Our purpose of this study was to investigate the tumor cell dissemination of ovarian carcinoma to the gradient lymph nodes of nude mice and its possible mechanism.

**Methods:** The mice models of VEGF-D over-expressed were built and the tumor growth and sentinel lymph nodes were evaluated weekly, while the visible lymph nodes and tumor masses were excised for histological examination using HE examination. Then Evan's Blue was conducted to observe the unveil lymphatic network. Subsequently, immunohistochemistry was performed to check the expression of relative genes. Meanwhile, microvessel counting was performed within the tumor tissues and measured using computer assisted morphometric analysis.

**Results:** The over-expression of VEGF-D promoted the tumor growth of ovarian carcinoma, facilitated the hyperplasia of tumor lymphatic and increased the intratumoral lymphatic vessel density. Besides, the up-regulation of VEGF-D induced the expression of MMP-2, which might be the underlying mechanism for the lymph metastasis in ovarian cancer.

**Conclusion:** It was a step-by-step progression from the inoculation of cancer cells, to the proliferation of the primary tumors, and then to the lymphatic metastases, in which VEGF-D and MMP-2 played vital roles.

## Background

Epithelial ovarian carcinoma (EOC) has by far the worst clinical outcome of all gynecological cancers, which is responsible for half of the deaths caused by female genital tract malignancy <sup>[1]</sup>. There were 295,414 patients newly diagnosed with EOC and 184,799 patients died of this cancer worldwide in 2018 <sup>[2]</sup>. Owing to the paucity of symptoms and insidious onset, more than 60% of patients are at advanced stages when they are diagnosed, and the prognosis is poor with an expected 5-year survival rate in the range of 10–20% <sup>[3–5]</sup>. Lymphatic metastasis is one of the main ways of tumor metastasis and is related to the prognosis of EOC patients. It has been reported that EOC patients has an incidence of 67.2% in Para-aortic and pelvic lymph node metastasis at advanced stage <sup>[6]</sup>, while the rate of lymph metastasis reached to 10%-30% even at early stage <sup>[7, 8]</sup>. Therefore, it is necessary to explore the underlying molecular mechanisms of lymph metastasis to improve the prognosis and prolong the overall survival of patients with EOC.

Lymphatic metastasis may occur at the early stage of most malignant tumors of the origin of the upper skin, which is associated with the special structure of the lymphatic vessel. It arises from the blind end of

the lymphatic capillaries, absorbs the liquid and macromolecular substance from the blood vessels and returns to the blood vessels at last. The space between the endothelial cells of the lymphatic capillaries is large and proteofibril combines the endothelial cells and extracellular matrix, which nearly has no heparan sulfate proteoglycan (HSPG) and fibronectin <sup>[9]</sup>. The increase of local matrix metalloproteinase degraded the internal and external substrate when the tissues became cancerous while the tumor cells are adhered to the fibronectin exposed to the endothelium, meanwhile the invasion and metastasis happen <sup>[10]</sup>. Lymph node metastasis is a multistep process, of which the mechanism remains unclear.

Vascular endothelial growth factor D (VEGF-D) is a member of VEGF family, which is the typical lymphangiopoiesis factor, which is often correlated with tumor metastasis and poor patient outcome <sup>[11]</sup>. Previous studies have proved that the abnormal expression of VEGF-D can act as a marker during the metastatic processes of various cancers <sup>[12-14]</sup>. Besides, VEGF-D may increase the diameter and the number of lymphatic vessels, thus providing increased surface area to facilitate lymphatic metastasis <sup>[10, 15]</sup>. However, the observation of progression and morphology in animal models remains unclear.

In present study, we established the metastasis model of ovarian carcinoma and observed the process and morph of lymph node metastasis in nude mice for two months. Then the types of metastasis morphology were described, while the underlying molecular mechanisms of lymphatic spread were preliminarily discussed. The importance of the diagnose at earlier stages and to seek routinely realistic effective screening program were considered as important and our finding may verify the clinical significance of VEGF-D as a promising target gene in the treatment of EOC.

## Methods

### Cell lines

Human serous cystadenocarcinoma cell lines SKOV-3 were obtained from American Type Culture Collection (ATCC; Rockville, MD) and cultured in RPMI-1640 medium (GIBCO) or in the medium with 400µg/ml G418-RPMI-1640 medium, supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin, and 100 microg/ml streptomycin. Then the cells were maintained in a 37°C-humidified incubator with 5% CO<sub>2</sub> atmosphere.

### Cell transfection

A vector containing a mouse VEGF-D cDNA (GenBank [NM\\_010216](#) GI: 6753873) or with the control vector pcDNA3.1 (+) was synthesized by Invitrogen (Carlsbad, CA) and transfected into the cells using Lipofectamin2000 (Invitrogen) according to the operation instruction.

### The establishment of the mice model and hematoxylin and eosin (HE) examination

Female athymic nude mice (BALB/c, 6-8-week-old, 18-20g) were provided by Sichuan University Animal Center, and housed in a pathogen-free animal facility, fed with the irradiated mouse chow and autoclaved

reverse-osmosis treated water. Before inoculation, mice were randomly assigned to three groups (12 mice/group): recombination VEGF-D experimental group (SR group), empty vector group (SV group) and not transfection group (SC group). Tumor cell inoculation was performed according to the protocols we had done before [16]. Briefly, the cells were harvested and suspended in serum-free medium. Then 50  $\mu$ l suspension liquid was injected subcutaneously into the left hind-footpads of the mice. Tumor growth and sentinel lymph nodes were evaluated weekly. Tumor volumes and the weight of the mice were evaluated consecutively for two months. The tumor volume was determined by the following formula: tumor volume ( $\text{mm}^3$ ) =  $0.52 \times \text{length (mm)} \times \text{width (mm)} \times \text{height (mm)}$ . All studies involving mice were approved by the Institute's Animal Care and Use Committee. Subsequently, three mice of each group were severally sacrificed using cervical dislocation on the 15 th, 30 th, 45 th and 60 th day. In detail, the mice's head was held down with thumb and forefinger, the tail was grasped using the other hand, causing the cervical vertebra to drop off. As a result, the spinal cord was severed from the cerebral marrow, and the mice was died immediately. The visible lymph nodes and tumor masses were excised for histological examination using HE examination.

### **Evan's Blue Injection and Analysis of Lymph Flux**

Evan's Blue was performed to observe the unveil lymphatic network. Evan's Blue was injected into the left footpads of the mice in each group using subcutaneous injection until lymph vessel (LV) draining to the inguinal lymph nodes were marked. At the timepoints of 20 and 30 minutes after injection, the popliteal nodes (**SLN**) were examined to determine the relationship between infusion speed and the increased lymph flow. Besides, the iliac lymph nodes on the lymph draining way from popliteal nodes were also assessed.

### **Immunohistochemistry**

Deparaffinized sections were placed into 0.01M citrate buffer (pH 6.0) and heated in an autoclave for 5 min for antigen retrieval. Then endogenous peroxidase activity was quenched in 3% hydrogen peroxide for 10 min. Subsequently, nonspecific binding sites were subsequently blocked with homoeotypic non-immunoglobulin of the secondary antibody at 37°C for 20 minutes. Sections were then incubated with the primary antibodies: mouse anti-human CA125 monoclonal antibody (Zhongshan -Golden Bridge, Beijing, China), CD40 polyclonal antibody (ab13545, Abcam, Cambridge, MA), anti-mouse VEGF-D monoclonal antibody (R&D Systems) (Santa Cruz Biotechnology, CA, USA), anti-MMP-2 antibody (ab86607; Abcam), rabbit anti-LYVE-1 (ab14917, Abcam) and anti-CD31 (cat.#ab28364, Abcam) at 4°C overnight in a humidified chamber. After being washed for three times, the sections were incubated with the secondary antibody for 40 minutes at 37°C, sequential incubation with streptavidin-biotin-peroxidase complex followed (7). The immunoreactions were visualized with diaminobenzidine (DAB) solution as chromogen, and the crimson precipitates were identified as positive staining. Counterstaining was performed with hematoxylin for 30 seconds. For the negative control, all of the reagents except for the primary antibody were used.

## **Computer-Assisted Morphometric Analysis**

Microvessel counting was performed within the tumor tissues and measured using computer assisted morphometric analysis. Five fields with abundant blood vessels and the highest microvessel density (MVD-hot spots) were first selected, which were captured by Spot digital camera at high-power field (HPF) and then parameters were evaluated using IP-Lab computer aided image analysis software.

## **Statistical Analysis**

Statistical analysis were conducted by the SPSS 22.0 software and all data were presented as Mean±SD. The Chi-Square test was used to analyze the Evan's Blue perfusion of lymph nodes. The difference between two groups was compared by students' t test, while that among three groups or above was analyzed by One-way ANOVA analysis. Differences with a P value below 0.05 were considered statistically significant.

## **Results**

### **The tumor growth in each group**

To explore the tumor growth, the tumor volume was measured at the 0, 20 th, 40 th and 60 th day after cell inoculation in each group. The results was shown in Figure 1, the tumor growth began to accelerate from the 15 th day after tumor cell implantation in SR group. Moreover, the tumor growth rate was quicker than that in SV and SC group at every subsequent point of observation since the 20 th day after inoculation ( $P<0.05$ , Fig. 1). What's more, the tumor growth was obviously expedited since the 25 th day. Nevertheless, there was no significant difference between SV group and SC group. These data demonstrated that the over-expression of VEGF-D promoted the tumor growth of Ovarian Carcinoma.

### **The hyperplasia of tumor lymphatic**

To investigate the hyperplasia of tumor lymphatic, Evan's Blue assay was implemented. The result manifested that the most lymphatic in draining areas and popliteal lymph nodes from mice in SR group were perfused with blue at the 20-minute time point, while infused functional lymphatic were hard to be found in the SV and SC groups (Fig. 2A-C). Furthermore, we checked the proliferation of tumor lymphatic. Consequently, the lymphatic was distinctly expanded in SR group, while the lumen of lymphatic vessels was much narrow even not visible in SC and SV groups (Fig. 2D-F). The data demonstrated that the expansion and proliferation of lymphatic could be enhanced by the over-expression of VEGF-D.

### **The dynamic metastasis of lymph nodes**

To research the metastasis of lymph nodes after tumor inoculation, consecutive observation for gradient lymph nodes of the mice in three groups was conducted for two months, including inspection and palpation of the popliteal and inguinal lymph node (sentinel lymph node). As consequence, the inguinal lymph nodes of two mice in SR group were palpable in two weeks after inoculation, while the popliteal

lymph node of one mouse was touched after four weeks of inoculation in SC group. Moreover, HE assay manifested that the nodal involvement occurred from the lower grading lymph nodes to the upper ones step by step (Fig. 3A-E). What's more, the difference of metastasis rates of gradient lymph nodes between SC and SV group wasn't significant. However, the metastasis of lymph nodes was dramatically quicker in SR group compared to that in SC or SV group after being inoculated for 45 day (Fig. 3F-I).

### **The distinction of nodal metastasis morph**

Although it is easy to confirm the typical metastasis focus using H&E staining, the atypical nodal involvement is hard to estimate. Herein, we analyzed the atypical nodal involvement via checking the expression of CA-125 and CD40 with immunohistochemical staining. The data displayed that there were various types of atypical nodal involvement according to detect the expression of CA-125 (Fig. 4A-C) and CD40 (Fig. 4D-F) in comparison to the primary tumor sections.

### **VEGF-D increases the intratumoral lymphatic vessel density**

To know whether VEGF-D played a role in blood vessel sprouting, immunohistochemical analysis was performed to detect the expression of LYVE-1 and CD31. Immunostaining with an antibody against LYVE-1 indicated that the lymph vessels density was obviously elevated while the immunostaining of CD31 showed that the density of microvessels was distinctly increased in SR group compared to that in SC and SV group (Fig. 5). These results suggested that the over-expression of VEGF-D could promote the proliferation of lymph vessels and the formation of tumor blood vessels.

### **MMP-2 was up-regulated by the over-expression of VEGF-D**

Furthermore, we explored that whether the promoting effects of VEGF-D on the tumor lymph nodes metastasis was correlated with the enhanced expression of MMP-2. Immunohistochemical analysis exhibited that MMP-2 were all positive expressed in three groups. Moreover, MMP-2 in SC and SV groups was weakly positive expressed (+) in tumor stroma instead of tumor cells (Fig. 6A, B), while more than 90% tumor cells and stroma of SR group showed much stronger staining for MMP-2 (+++) (Fig. 6C), which was properly corresponded with the over-expression of VEGF-D (Fig. 6D-F). All above, the tumor lymph metastasis was intensified by the over-expression of MMP-2 induced by VEGF-D.

## **Discussion**

Ovarian carcinoma is the fifth leading cause of death among all gynecological malignancies in development countries<sup>[17]</sup>. Due to the lack of typical clinical symptoms and available precise biomarkers, 70% patients have widespread metastasis at advanced stages when diagnosed<sup>[18]</sup>. Although the overall survival of patients with ovarian carcinoma has greatly improved along with the advances in clinical diagnosis and treatment, the effective treatment and control method still lack for patients at advanced stage, especially for those with lymph metastasis. Therefore, it is central to uncover the underlying mechanism of tumor metastasis so as to develop effective therapeutic strategy. Abundant investigations

have been done on angiogenesis and vascular relevant molecules, and much progress have been made, while with respect to the lymphatic spread, much smaller number of researches has been done.

The observation and definition of nodal invasion is the basement for estimate the lymphatic spread, which is the first step of tumor dissemination. To our knowledge, there are no previous reports about the determination of metastasis. In our study, we established the lymphogeneous high metastasis animal model with SKOV-3 cells transfected with VEGF-D <sup>[16]</sup>, and explored the underlying mechanisms of the lymph metastasis.

VEGF-D, an angiogenic and lymphangiogenic glycoprotein, can facilitate tumor growth and distant organ metastasis <sup>[11]</sup>. Accumulated evidences have proved the expression of VEGF-D is usually connected with tumor metastasis and poor patient outcome. For instance, Wei et al., found VEGF-D was involved and played an important role in gallbladder cancer progression, which indicted that VEGF-D was a potential molecular target in the treatment of gallbladder cancer <sup>[19]</sup>. VEGF-D was highly expressed and could predict the lymph node metastasis in patients with urothelial carcinoma of the bladder at the time of radical cystectomy, which combined with the low MMP-2 serum levels <sup>[14]</sup>. Moreover, the up-regulation of VEGF-D was significantly correlated with CXCR4, CCR7 and VEGF-C in the lymph node metastasis of patients with cervical cancer <sup>[20]</sup>. Besides, we had verified that VEGF-D could promote the lymph metastasis <sup>[16]</sup>. Our study revealed that the over-expression of VEGF-D was positive to the tumor growth, indicating that VEGF-D could raise the proliferative capability of tumor cells. It was reported that the lower the degree of differentiation of tumor cells, the stronger the ability of cell proliferation and invasion, the stronger the sex, the more malignant it is <sup>[21]</sup>. However, whether VEGF-D could increase the malignancy of the tumor via strengthening the tumor cell proliferation needs further studies.

Sentinel lymph node (SLN) has been demonstrated to become functional blood vessel-enriched and lymph vessel/sinus-enriched before metastasis formation, and there are reorganizations of the lymphatic channels and the vasculature before the establishment of metastasis in the node <sup>[22]</sup>. The dilation of the lymph sinuses is correlated with the primary tumor weight and the proliferation rate of the endothelial cells is significantly increased <sup>[23]</sup>. In our study, we found that there were a few isolated tumor cells in enlarged marginal sinus of SLN in SR group before apparent metastasis focus was established, which might be related to the dilation of lymph sinuses. In addition, we discovered that it is not a very short interval from formation of primary tumor mass to nodal involvement, comprising four steps. Firstly, presence of increased lymphatic sinus in size. Secondly, invasion of single or scattered cancer cells via sinus. Thirdly, formation of cancer cell clusters in the sinus or into the parenchyma. Finally, cancer cells defeated the lymphocytes and proliferated in the cortex. What we have found suggests and emphasizes it is vital to diagnose at earlier stages and to seek routinely realistic effective screening program.

Moreover, we investigated the morphology of the invaded nodes which displayed that some types of atypical morph of metastatic tumor cells were occurred in the involved lymph nodes. Herein, we speculated this phenomenon might occur in clinical cases. Many papers have revealed that the poor

patient survival of unsuitable treatment was caused by missing microinvasion. Consistent with this, we assumed missing atypical metastases also resulted in the worse outcome of patients. It should be argued that immunostaining for CA125 or CD31 might be a promising approach to tell the atypical lymphatic metastasis, which deserved further investigations.

Furthermore, the role of VEGF-D and the underlying mechanisms of ovarian tumor metastasis was investigated. A high tendency of earlier and dilated lymph node appeared in SR group, and enlargement, fixation and harder feature (osseous metaplasia) of lymph nodes seemed to be indicators of metastases.

Finding that microscopic blood vessels were increased in VEGF-D overexpression tumors was not anticipated, which may be another reason for tumorigenesis and tumor growth caused by VEGF-D. It may be due to the activation between VEGF-D and up-regulated VEGFR-3 on blood vessels within tumors, and to the increased microscopic vessel density caused by strong MMP-2 expression. It could not be excluded the possibility that VEGF-D bind to the VEGFR-3-VEGFR-2 heterodimers <sup>[24, 25]</sup>. Currently, we used Evan's blue dye to explore tumor-draining lymph flux. More rapid dye perfusion into the SR lymph nodes was observed, both in the popliteal and iliac nodes (more central lymph nodes), which indicated an accelerated lymph flow both into and out of lymph nodes. We deduced that VEGF-D-induced lymphangiogenesis and enlarged lymphatic sinus might facilitate tumor cell transport via accelerate lymph flow and finally act as a stimulator of lymphatic spread.

## Conclusions

In conclusion, our study observed morphology and progress of tumor cell metastasis and further investigated the correlation among tumorigenesis, lymphangiogenesis, angiogenesis and VEGF-D expression, which showed that in addition to lymphatic expansion stimulated by VEGF-D we have demonstrated before, enlargement of lymphatic sinus in LNs and increased lymph flux also ease cancer cell invasion. Original idea did not indicate mouse VEGF-D, which was ligand to VEGFR-3, would promote angiogenesis. Our study verifies cancer spread via lymphatic is a step-by-step progression, and suggests the treatment against any phase of this progression will be promising, but what is the most important is to diagnose at an earlier stage. Atypical metastases as well as microinvasions are both barriers for appropriate treatment selection. Immunostaining for CA125 or CD31 may be a promising approach to tell the missable lymphatic metastasis. We hope that our findings will ease the experimental research on metastasis later. More studies and consideration should be performed in this field.

## List Of Abbreviations

Full name	abbreviation
Epithelial ovarian carcinoma	EOC
Vascular endothelial growth factor D	VEGF-D
Lymph vessel	LV
Matrixmetallo proteinase-2	MMP-2
Carbohydrate antigen-ca 125	CA-125
Sentinel Lymph Node	SLN

## Declarations

### Ethics approval and consent to participate

This study was approved by the society for the Ethics of Animal Experiments of Shandong University.

### Consent for publication

Not applicable.

### Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

### Competing interests

The authors declare that they have no competing interests.

### Funding

Not applicable.

### Authors' contributions

LC Du and FH Kong performed the experiment and were major contributors in writing the manuscript. Q Yang, YQ Li, PKi Ding, GX Ding and XM Wang participated in the experiment and collected the data. B Kan and YP Wang analyzed the data. XS Tian and YR Zhao who were the joint corresponding author reviewed and edited the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

Not applicable.

# References

1. S. F. Hsieh, H. Y. Lau, H. H. Wu, et al. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. *Int J Environ Res Public Health* 2019; 16(4):
2. F. Bray, J. Ferlay, I. Soerjomataram, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68(6): 394-424.
3. L. Rosanò, F. Spinella, D. Salani, et al. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. *Cancer Res* 2003; 63(10): 2447-53.
4. K. Hibbs, K. M. Skubitz, S. E. Pambuccian, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. *Am J Pathol* 2004; 165(2): 397-414.
5. Y. Dong, A. Kaushal, L. Bui, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. *Clin Cancer Res* 2001; 7(8): 2363-71.
6. L. C. Du, X. C. Chen, D. Wang, et al. VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. *Reprod Biol Endocrinol* 2014; 12(14).
7. F. di Re, G. Baiocchi, R. Fontanelli, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. *Gynecol Oncol* 1996; 62(3): 360-5.
8. M. Suzuki, M. Ohwada, T. Yamada, et al. Lymph node metastasis in stage I epithelial ovarian cancer. *Gynecol Oncol* 2000; 79(2): 305-8.
9. A. Nakayama, A. Ogawa, Y. Fukuta, et al. Relation between lymphatic vessel diameter and clinicopathologic parameters in squamous cell carcinomas of the oral region. *Cancer* 1999; 86(2): 200-6.
10. S. A. Stacker, M. E. Baldwin, M. G. Achen. The role of tumor lymphangiogenesis in metastatic spread. *FASEB J* 2002; 16(9): 922-34.
11. I. Papiewska-Pająk, A. Balcerczyk, E. Stec-Martyna, et al. Vascular endothelial growth factor-D modulates oxidant-antioxidant balance of human vascular endothelial cells. *J Cell Mol Med* 2017; 21(6): 1139-1149.
12. W. Yang, K. Klos, Y. Yang, et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. *Cancer* 2002; 94(11): 2855-61.
13. W. G. Hu, J. W. Li, B. Feng, et al. Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. *Eur Surg Res* 2007; 39(4): 229-38.
14. T. Benoit, E. X. Keller, P. Wolfsgruber, et al. High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer. *Med Sci Monit* 2015; 21(2266-74).

15. R. K. Jain, B. T. Fenton. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? *J Natl Cancer Inst* 2002; 94(6): 417-21.
16. Q. Guo, X. Du, Y. Zhao, et al. Ischemic postconditioning prevents renal ischemia reperfusion injury through the induction of heat shock proteins in rats. *Mol Med Rep* 2014; 10(6): 2875-81.
17. L. Zhan, Y. Zhang, W. Wang, et al. Autophagy as an emerging therapy target for ovarian carcinoma. *Oncotarget* 2016; 7(50): 83476-83487.
18. Y. Li, C. Tan, L. Liu, et al. Significance of blood and salivary IEX-1 expression in diagnosis of epithelial ovarian carcinoma. *J Obstet Gynaecol Res* 2018; 44(4): 764-771.
19. W. Lin, L. Jiang, Y. Chen, et al. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. *Cancer Lett* 2012; 314(2): 127-36.
20. Y. Dai, R. Tong, H. Guo, et al. Association of CXCR4, CCR7, VEGF-C and VEGF-D expression with lymph node metastasis in patients with cervical cancer. *Eur J Obstet Gynecol Reprod Biol* 2017; 214(178-183).
21. M. E. Baldwin, B. Catimel, E. C. Nice, et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. *J Biol Chem* 2001; 276(22): 19166-71.
22. C. N. Qian, B. Berghuis, G. Tsarfaty, et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. *Cancer Res* 2006; 66(21): 10365-76.
23. S. Hirakawa, L. F. Brown, S. Kodama, et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. *Blood* 2007; 109(3): 1010-7.
24. M. Detmar, S. Hirakawa. The formation of lymphatic vessels and its importance in the setting of malignancy. *J Exp Med* 2002; 196(6): 713-8.
25. J. Dixelius, T. Makinen, M. Wirzenius, et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. *J Biol Chem* 2003; 278(42): 40973-9.

## Figures






Figure 1

The tumor growth in each group after tumor cell implantation. In SR group, the tumor growth was much faster than that in SV and SC group.\* P<0.05, \*\*P<0.01, \*\*\*P<0.001.




## Figure 2

The functional lymphangiography of lymph vessel using Evan's Blue. Red blood vessel (BV) indicated by arrows occurred in the tumor surface (TS) in SC group (A) and SV group (B) without perfused functional lymphatic vessels (LV) at 20-minute time point. In the tumor surface of SR group (C) there are dense perfused lymphatic vessel webs (arrow) meanwhile. Moreover, the lymphatic was distinctly expanded in SR group, while the lumen of lymphatic vessels was much narrow even not visible in SC and SV




## Figure 3

Histological analysis of metastasis progression of tumor-draining gradient lymph nodes in nude mice after consecutive examination. There were some migrating tumor emboli (arrow) founded in the local dilated lymphatic capillaries among adjacent peritumoral connective tissue in SR group after being inoculated for 15 days (A), while only a few isolated tumor cells (arrow) in enlarged marginal sinus of the first step tumor-draining LN (Sentinel lymph node) without apparent metastasis focus (B). After being inoculated for 30 days, small clusters of metastatic focus (arrow) were found in the cortical lymphatic sinus especially in SR mice (C), while clumpy deposits of metastatic carcinoma (arrow) could be observed in tumor-draining LNs (D) after being inoculated for 45 days. Moreover, metastatic foci (arrow) occupied almost the entire LN (E) after being inoculated for 60 days. In popliteal LNs, metastasis was found in SR group 30 days after inoculation, and 45 days later its metastasis rate reaches 36.1%, 60 days reaches 81.9% (F). In inguinal LNs, SR group was found metastasis 30 days after inoculation, and its 45 days metastasis rate reaches 40.2%, 60 days later reaches 75.1% (G). In parailiac LNs, metastasis was not found in SR group on day 30 after inoculation, however, metastasis rate reaches 19%, 60 day reaches 76.4% on day 45 (H). In renal hilum LNs, metastasis was also not found in SR group until 45 days after implantation. Metastasis rate on Day 45 reaches 12%, Day 60 reaches 48.7% (I).




**Figure 4**

Immunohistochemical analysis of metastasis progression of tumor- draining lymph nodes. There were a few isolated CA125-positive tumor cells (arrow) in enlarged marginal sinus of first step draining LN (Sentinel lymph node) without apparent metastasis focus 15 days after inoculation in SR group (A). Typical metastases focus (B) and atypical metastases focus (arrow) of third step draining LN (C) were positive for CA125 antibody 60 days after inoculation in SR group. There were many isolated CD40-positive tumor cells (arrow) in enlarged marginal sinus of third step draining LN without apparent metastasis focus 30 days after inoculation in SR group (D). Typical metastasis focus (E. arrow) and atypical metastasis focus with osseous metaplasia /Calcification (arrow) of third step draining LN (F) were positive for CD-40 antibody 45 days after inoculation in SR group.



**Figure 5**

Intratumoral lymphatic vessel sprouting and blood vessel density of different groups via immunohistochemical analysis. There were sparse LYVE-1- positive neonatal lymphatic vessel (arrow) in the tumors of SC group (A) and SV group (B) after being inoculated for 60 days. However, rich nascent lymphatic microvessel sprouts with dilated lumina indicated by arrows were present among tumor cells of SR group (C). Representative sections for CD-31-positive blood microvessels (arrows) from tumor tissues of three groups were presented in SC group (D), SV group (E) and SR group (F). SR group displayed a little increased blood microvessel density after being inoculated for 60 days in compared with the controls.



**Figure 6**

The microscopic column showed the expression of matrix metalloproteinase-2 (MMP-2) and VEGF-D of tumor tissues in different groups. In comparison with the weak stromal but cellular staining (+) in SC group (A) and SV group (B), it was obviously stronger cellular staining (+++) in tumor tissue of SR group (C). A majority of tumor cells in SC (D) and SV (E) group as well as interstitium showed negative or only very weak staining ( $\pm$ ) for VEGF-D. However, SR group showed much stronger staining (+++), indicating the overexpression of VEGF-D (F), which was properly corresponded with the expression of MMP-2.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ARRIVEchecklist.docx](#)